Stock Detail
SEATTLE GENETICS INC
Biotechnology
SGEN @ Yahoo Finance | SGEN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $15.88 | $16.30 | $-0.19 | -1.18% | 0.00 | $16.07 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $15.98 | $15.80 | 1.1M | 1.83B | 2.44M | -10.88 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 16.49 | 16.18 | 15.99 | 15.68 | 15.49 |
Stock Profile
Seattle Genetics, Inc. develops monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. The company's monoclonal antibody-based technologies include genetically engineered monoclonal antibodies, antibody-drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT), which are used to develop monoclonal antibodies that can kill target cells on their own, as well as increase the potency of monoclonal antibodies. Its product candidate, SGN-30, is in phase II clinical trials, which is used for the treatment of Hodgkin's disease and systemic anaplastic large cell lymphoma; and SGN-15 has completed a phase II clinical trial for use in the treatment of nonsmall cell lung cancer. The company's SGN-40 is in phase I clinical trials in patients with multiple myeloma. In addition, it has four product candidates in preclinical development: SGN-35, SGN-70, SGN-75, and SGN-17/19. The company is conducting preclinical development tests of SGN-35 for the treatment of hematologic malignancies, such as Hodgkin's disease and some types of nonHodgkin's lymphoma. SGN-75 is an ADC composed of an anti-CD70 monoclonal antibody. The CD70 antigen is expressed on renal cancer, nasopharyngeal carcinoma, and certain hematologic malignancies. SGN-17/19, an ADEPT product candidate, is being developed for the treatment of metastatic melanoma. The company has collaboration agreements with Genentech, Celera Genomics Group, UCB Celltech, Protein Design Labs, PSMA Development Company LLC, CuraGen, and Bayer for its ADC technology; and with Genencor for its ADEPT technology. Seattle Genetics was co-founded in 1997 by H. Perry Fell and Clay B. Siegall. The company is headquartered in Bothell, Washington.